Home・Aandelen Lijst・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

2.3 4.07

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.16

Max

2.37

Belangrijke statistieken
By Trading Economics
Inkomsten	14M -1M
Verkoop	16M 21M
EPS	-0.003
Winstmarge	-4.943
Werknemers	81
EBITDA	15M 657K

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+119.65% upside

Dividenden
By Acuity
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	324M 1B
Vorige openingsprijs	-1.77
Vorige sluitingsprijs	2.3

Nieuwssentiment

By Acuity

50%

155 / 340 Rangschikking in Healthcare

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 jul 2026, 19:03 UTC

Lexicon Pharmaceuticals Inc is trading lower today, breaking a trend of higher daily closes. Broader market declines and falling oil prices may influence sentiment.

24 jul 2026, 20:07 UTC

Lexicon Pharmaceuticals Inc shares are lower today, reversing from earlier gains amid broader market volatility influenced by falling oil prices and inflation concerns.

22 jul 2026, 19:02 UTC

Lexicon Pharmaceuticals Inc shares are lower today, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

21 jul 2026, 19:42 UTC

Lexicon Pharmaceuticals is higher as the market gains momentum, driven by strong performances from major companies and a resurgence in semiconductor stocks.

20 jul 2026, 19:06 UTC

Lexicon Pharmaceuticals Inc shares are lower today, following three days of gains. Broader market declines are linked to rising US Treasury yields and oil prices above $90.

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

119.65% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.03 USD 119.65%

Hoogste 6 USD

Laagste 3.1 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Lexicon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

155 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.